Dumayo, William B.
HRN: 09-87-17 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/21/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/21/2022
10/25/2022
IVT
2.25g
Q8
UTI; CAP MR
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractPneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes